| Medical and Health Sciences | 2021-2025 | 388 | IT 27 | 99.92 |
| Hematology | Lifetime | 79 | IT 7 | 99.56 |
| Medical Genetics | Lifetime | 229 | IT 20 | 98.20 |
| Immunology | Lifetime | 579 | IT 21 | 98.26 |
| Hematology | 2021-2025 | 17 | IT 1 | 99.68 |
| Medical Genetics | 2021-2025 | 97 | IT 10 | 96.65 |
| Immunology | 2021-2025 | 298 | IT 11 | 92.76 |
| Surgery | 2021-2025 | 893 | IT 62 | 91.76 |
| Genetics | 2021-2025 | 360 | IT 11 | 90.21 |
| Infectious Diseases | 2021-2025 | 476 | IT 30 | 89.96 |
| Internal Medicine | 2021-2025 | 113 | IT 11 | 82.80 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 938 | IT 35 | 79.68 |
| Hemophilia Treatment and Research | Lifetime | 3 | IT 2 | 99.74 |
| Platelet Disorders and Treatments | Lifetime | 26 | IT 4 | 99.56 |
| Hemostasis and retained surgical items | Lifetime | 5 | IT 3 | 99.49 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 30 | IT 3 | 99.39 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 42 | IT 3 | 99.43 |
| Complement system in diseases | Lifetime | 31 | IT 4 | 99.31 |
| Blood groups and transfusion | Lifetime | 71 | IT 9 | 99.09 |
| Blood properties and coagulation | Lifetime | 55 | IT 5 | 99.02 |
| COVID-19 Clinical Research Studies | Lifetime | 322 | IT 37 | 98.63 |
| Renal Diseases and Glomerulopathies | Lifetime | 149 | IT 16 | 98.99 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 92 | IT 10 | 97.65 |
| Cancer-related gene regulation | Lifetime | 581 | IT 8 | 97.31 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 976 | IT 60 | 97.65 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 348 | IT 46 | 97.46 |
| Long-Term Effects of COVID-19 | Lifetime | 898 | IT 149 | 94.55 |
| Blood disorders and treatments | Lifetime | 358 | IT 20 | 95.96 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 767 | IT 73 | 96.83 |
| COVID-19 and healthcare impacts | Lifetime | 962 | IT 112 | 91.95 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 1 | IT 1 | 99.64 |
| Hemophilia Treatment and Research | 2021-2025 | 1 | IT 1 | 99.87 |
| Platelet Disorders and Treatments | 2021-2025 | 2 | IT 1 | 99.65 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 9 | IT 1 | 99.19 |
| Blood groups and transfusion | 2021-2025 | 14 | IT 4 | 98.88 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 10 | IT 2 | 97.92 |
| Blood disorders and treatments | 2021-2025 | 13 | IT 3 | 97.40 |
| Complement system in diseases | 2021-2025 | 25 | IT 5 | 97.99 |
| COVID-19 Clinical Research Studies | 2021-2025 | 576 | IT 64 | 97.45 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 287 | IT 22 | 96.80 |
| Virus-based gene therapy research | 2021-2025 | 311 | IT 16 | 92.65 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 314 | IT 36 | 92.65 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 450 | IT 49 | 91.81 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 469 | IT 42 | 91.93 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 537 | IT 74 | 89.13 |
| Hemostasis and retained surgical items | 2021-2025 | 65 | IT 2 | 83.36 |
| Blood properties and coagulation | 2021-2025 | 167 | IT 5 | 84.11 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 835 | IT 58 | 53.39 |
